

Page Proof Instructions and Queries

Please respond to and approve your proof through the "Edit" tab, using this PDF to review figure and table formatting and placement. This PDF can also be downloaded for your records. We strongly encourage you to provide any edits through the "Edit" tab, should you wish to provide corrections via PDF, please see the instructions below and email this PDF to your Production Editor.

Journal Title: Clinical Rehabilitation Article Number: 938423

Thank you for choosing to publish with us. This is your final opportunity to ensure your article will be accurate at publication. Please review your proof carefully and respond to the queries using the circled tools in the image below, which are available in Adobe Reader DC* by clicking **Tools** from the top menu, then clicking **Comment**.

Please use *only* the tools circled in the image, as edits via other tools/methods can be lost during file conversion. For comments, questions, or formatting requests, please use **I**. Please do *not* use comment bubbles/sticky notes **()**.



*If you do not see these tools, please ensure you have opened this file with **Adobe Reader DC**, available for free at get.adobe.com/reader or by going to Help > Check for Updates within other versions of Reader. For more detailed instructions, please see us.sagepub.com/ReaderXProofs.

No.	Query
GQ1	Please confirm that all author information, including names, affiliations, sequence, and contact details, is correct.
GQ2	Please confirm that the funding and conflict of interest statements are accurate.
GQ3	Please note that we cannot add/amend ORCID iDs for any article at the proof stage. Following ORCID's guidelines, the publisher can include only ORCID iDs that the authors have specifically validated for each manuscript prior to official acceptance for publication.
1	Please check the edits made on Figure 2 caption
2	Please check the edits made on figure 4
3	Please provide publisher location or active URL for reference 18.
4	Please provide conference location for refernce 26.

CLINICAL REHABILITATION

Does cycling induced by functional electrical stimulation enhance motor recovery in the subacute phase after stroke? a systematic review and meta-analysis Clinical Rehabilitation I–14 © The Author(s) 2020 Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/0269215520938423 journals.sagepub.com/home/cre



Emilia Ambrosini¹, Monica Parati², Giorgio Ferriero³, Alessandra Pedrocchi¹ and Simona Ferrante¹ [GQ: 1]

Abstract

Objective: To investigate the effects of cycling with functional electrical stimulation on walking, muscle power and tone, balance and activities of daily living in subacute stroke survivors.

Data Sources: Ten electronic databases were searched from inception to February 2020.

Review methods: Inclusion criteria were: subacute stroke survivors (<6months since stroke), an experimental group performing any type of cycling training with electrical stimulation, alone or in addition to usual care, and a control group performing usual care alone. Two reviewers assessed eligibility, extracted data and analyzed the risks of bias. Standardized Mean Difference (SMD) or Mean Difference (MD) with 95% Confidence Intervals (CI) were estimated using fixed- or random-effects models to evaluate the training effect. **Results:** Seven randomized controlled trials recruiting a total of 273 stroke survivors were included in the meta-analyses. There was a statistically significant, but not clinically relevant, effect of cycling with electrical stimulation compared to usual care on walking (six studies, SMD [95% CI]=0.40 [0.13, 0.67]; P=0.004), capability to maintain a sitting position (three studies, MD [95% CI]=7.92 [1.01, 14.82]; P=0.02) and work produced by the paretic leg during pedaling (2 studies, MD [95% CI]=8.13 [1.03, 15.25]; P=0.02). No significant between-group differences were found for muscular power, tone, standing balance, and activities of daily living.

Conclusions: Cycling training with functional electrical stimulation cannot be recommended in terms of being better than usual care in subacute stroke survivors. Further investigations are required to confirm these results, to determine the optimal training parameters and to evaluate long-term effects.

Neuroengineering and Medical Robotics Laboratory,

Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, MI, Italy *Alessandra Pedrocchi and Simona Ferrante have equally contributed to this work as last Co-Author.

Corresponding author:

Emilia Ambrosini, Neuroengineering and Medical Robotics Laboratory, Department of Electronics, Information and Bioengineering, Politecnico di Milano, Piazza Leonardo da Vinci 32, 20133, Milan, MI 20133, Italy. Email: emilia.ambrosini@polimi.it

²Bioengineering Laboratory, Scientific Institute of Milan, Istituti Clinici Scientifici Maugeri IRCCS, Milan, Italy

³Physical and Rehabilitation Medicine Unit, Scientific Institute of Tradate, Istituti Clinici Scientifici Maugeri IRCCS, Lissone, Tradate, Italy

Stroke, rehabilitation, functional electrical stimulation, cycling, meta-analysis

Received: 26 August 2019; accepted: 9 June 2020

Introduction

Functional electrical stimulation is a well-established intervention for motor recovery after stroke.^{1,2} Lower limb functional electrical stimulation has been applied in different modalities, multichannel or single-channel to the peroneal nerve, overall showing a positive effect on gait performance.³⁻⁵ In the last decade, cycling induced by functional electrical stimulation has been proposed as an alternative treatment for gait recovery after stroke.^{6,7} Indeed, cycling entails an asymmetric coordinated activation of the two legs similar to locomotion,^{8,9} but can be safely applied soon after stroke, since it does not require the capability to maintain upright posture. A recent systematic review with meta-analysis has quantitatively summarized the current evidence about the effects of cycling with and without functional electrical stimulation on functional mobility after stroke.¹⁰ The Authors concluded that cycling has a positive effect on walking speed, walking ability and balance, and benefits on balance were increased when functional electrical stimulation was added to cycling training. However, this review was mainly focused on cycling training in general, and just one single-outcome meta-analysis, including only two studies, was conducted to compare the effects of cycling induced by functional electrical stimulation to usual care. Furthermore, a mixed population, including both subacute and chronic stroke survivors, was considered. The only reviews specifically focused on cycling induced by functional electrical stimulation were qualitative and targeted on individuals with spinal cord injury.^{11–13}

This systematic review with meta-analyses aimed at gathering and synthetizing the current evidence about the effects of cycling induced by functional electrical stimulation in the subacute phase after stroke. The primary aim was to analyze whether cycling induced by functional electrical stimulation represents an effective alternative or integrative treatment to usual care for promoting walking abilities over short distances in these patients. Different secondary outcome measures were also appraised, including muscle strength, spasticity, balance, cycling performance and basic activities of daily living.

Methods

This study was undertaken in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) statements.¹⁴

Identification of the studies

The following electronic databases Cochrane Library, Pubmed, Embase, Google Scholar, IEEExplore, PsychINFO, Scopus, Web of Science, ClinicalTrial. gov, WHO International Clinical Trials Registry, OpenGrey database were searched for their inception up to February 2020. Methodological search filters by study designs and outcomes were not applied to minimize incomplete retrieval of identified research. No language, date and document format restrictions were applied to reduce reporting bias. The following keywords were combined in the search strategy: electrical stimulation. neuromuscular stimulation, Functional Electrical Stimulation (FES), Neuro-Muscular Electrical Stimulation (NMES), Functional Neuro-muscular Stimulation (FNS), cycling, pedaling, ergometry, cycle ergometry, cycle training, stroke, cerebrovascular accident (CVA). The full search strategy is available in Supplemental Appendix 1. Reference lists of all potentially eligible articles identified from the search strategy were also screened to identify any further studies for inclusion.

Eligibility criteria

Studies were included if they implemented an intervention based on cycling induced by functional electrical stimulation alone or in addition to usual care and if they compared its effects to usual care and/or any other treatments involving no types of electrical muscle stimulation. Randomized, quasi-randomized or crossover trials with a longitudinal design were considered. Studies were excluded if only abstract was available or numerical scores of outcomes were not reported. Case reports, editorials, letters, commentaries, and review articles were also excluded.

Participants of included studies were adult patients (age 18+ years) with a diagnosis of single ischemic or hemorrhagic stroke in the subacute phase (i.e. less than six months since first stroke). No eligibility criteria were defined based on outcome measures, which were classified based on the International Classification of Functioning, Disability and Health¹⁵ to facilitate content comparisons and interpretations.

Titles and abstracts of the identified papers were independently evaluated by two review authors (EA, MP). Full texts of all potentially relevant articles were then obtained and assessed by each review author (EA, MP). After full text review, study eligibility was determined. Data from eligible studies were extracted by one review author (MP) using a structured form, including study design, number of patients, patient's demographic and clinical characteristics, intervention protocol, comparison groups, and results of the outcomes. A second review author (EA) confirmed the data extraction accuracy and any disagreement was resolved by discussion. When relevant information was missing, authors of primary studies were contacted.

Risk of bias assessment

The risk of bias of each study was assessed using a domain-based evaluation tool and different criteria from each domain were separately evaluated: (1) selection bias (random sequence generation; allocation concealment; group similarity at baseline); (2) performance bias (blinding of participants; blinding of personnel; co-interventions; compliance); (3) detection bias (blinding of outcome assessment; timing of outcome assessment); (4) attrition bias (incomplete outcome data; intention-to-treat analysis); (5) reporting bias (selective reporting). Two review authors (EA, MP) independently assessed the risk of

bias of each included studies using the revised extension¹⁶ of the criteria described by Cochrane Handbook for Systematic Reviews of Interventions.¹⁷ For each criterion, a "low risk," "high risk" or "unclear risk" of bias was assigned. Each study was classified as "low risk" of bias, if at least six of the appraised criteria were considered as "low risk," whereas if more than six criteria were assessed as "high" or "unclear risk," the study was considered at "high risk" of bias.

Measures of treatment effects

The results of individual studies were collected and combined when possible through meta-analysis techniques,¹⁸ to evaluate the effect of cycling induced by functional electrical stimulation with respect to usual care at short- and/or intermediate-term follow-up.

Outcome data were pooled in categories of outcome measures based on the sub-domains of the International Classification of Functioning, Disability and Health classification, as reported in Supplemental Appendix 2. Outcomes measured closest to four weeks were considered short-term follow-up, outcomes measured closest to six months were considered intermediate-term follow-up.¹⁷

For continuous outcome measures the intervention effects were evaluated through the Mean Difference (MD) or the Standardized Mean Difference (SMD) based on Hedges' *g*, along with the 95% Confidence Interval (CI), of post-intervention values.¹⁹ However, if there was a baseline imbalance, which was defined as a between-group difference at baseline higher than the minimal clinically important difference, in at least one study, the meta-analysis for that specific outcome was conducted on change values.¹⁷

Heterogeneity among studies was assessed using the I² statistic and the Chi² test.²⁰ In case of high heterogeneity, that is, I² >50%, a randomeffect model was applied, otherwise a fixed-effect model was preferred.²¹

All analyses were performed using Review Manager 5.3 software.²² The null hypothesis of no statistical difference was rejected if the *P*-value was <0.05.

Missing standard deviations or mean values were retrieved by contacting the authors of primary studies or estimated by means of imputation from available data.²³

Data synthesis

The overall quality of the evidence for each category of outcome measures was evaluated by means of the Grades of Recommendation Assessment, Development and Evaluation (GRADE) system.²⁴ For each outcomes category, the following factors were assessed: limitations in study design (if the majority of the studies was considered at "high risk" of bias), inconsistency (if there was an unexplained high heterogeneity among studies, e.g. $I^2>25\%$), and imprecision (overall sample size lower than 300). The quality started as "high" when all the studies included in the meta-analysis were randomized controlled trials and was reduced by one level for each of the unmet factors.

The main results of this systematic review were reported in the "Summary of findings table" following the guidelines of the Cochrane collaboration.^{18,24}

Results

Study selection

Figure 1 reports the PRISMA flowchart of the study: 7 independent studies from 10 published articles^{25–34} met the eligibility criteria and were included in this systematic review. The list of included studies in alphabetic order is reported in Supplemental Appendix 3.

Characteristics of included studies

The main characteristics of the included studies are summarized in Table 1.

In summary, they are all randomized controlled trials set in inpatient rehabilitation units. They recruited a total of 273 subjects with a mean (SD) age of 62 (6) years, ranging from 53 to 74 years and mean (SD) time after stroke at recruitment of 40 (18) days, in the range of 15 to 60 days.

In five studies, the experimental group performed active cycling augmented by functional electrical stimulation, delivered to both legs (S2) or only to the paretic leg (S3,S4,S6,S7); in the two remaining studies (S1,S5), the experimental group performed passive cycling augmented by functional electrical stimulation delivered to both legs. The control groups principally received usual care (S1-S5,S7) and active or passive cycling (S1,S3,S6,S7). When reported, both experimental and control groups were trained for an equal amount of time. The duration of the intervention ranged from three to eight weeks, while the frequency varied from three to six times per week. The total number of training sessions ranged between 12 (S3) and 48 (S7). The drop-out rate varied between 0% to 17% at the end of the intervention. The reasons for dropout were reported in all studies and were not correlated to the intervention group.

Methodological quality

Supplemental Figure S1 shows the summary of the risk of bias assessment. Overall, four studies (S1–S4) were evaluated as "low risk" of bias. The most frequent source of bias was performance bias, because no studies provided blinding of personnel, as expected, since it is unfeasible for this type of training, and only one study (S1) provided an adequate blinding of participants, implementing a cycling training with placebo functional electrical stimulation.

Treatment Effects at short-term follow-up

Figure 2 reported the results of the meta-analyses at short-term follow-up.

Six studies were included in the meta-analysis of the primary outcome, that is, walking short distances, and a significant effect (SMD [95% CI] = 0.40 [0.13, 0.67]; P = 0.004; 221 patients) was found in favor of the experimental group (Figure 2(a)) with a moderate quality of the evidence. Since a baseline imbalance was found in one study (S6, between-group difference of $0.27 \text{ m/s}^{35,36}$ at baseline), this meta-analysis was conducted on change values.

For secondary outcome measures, no baseline imbalance was found, and thus meta-analyses were



Figure 1. PRISMA flowchart of the literature search process.

performed on post-treatment values. Muscle power functions of the lower limbs showed a tendency, not statistically significant, in favor of the experimental group (SMD [95% CI] = 0.23 [-0.05, 0.51]; P = 0.11; 194 patients; five studies) with a moderate quality of the evidence (Figure 2(b)). Muscle tone (SMD [95% CI] = 0.49 [-1.74, 2.71]; P = 0.67; 91 patients; two studies) and capability to maintain a standing position (SMD [95% CI] = 0.52 [-0.41, 1.45]; P = 0.28; 173 patients; four studies) revealed no significant differences between groups with a low quality of the evidence (Figure 2(c) and (d)). A significant difference in favor of the experimental group was found for the capability to maintain a sitting position (MD [95% CI] = 7.92 [1.01, 14.82]; P = 0.02; 118 patients; three studies) (Figure 2(e)) with a moderate quality of the evidence. Two studies evaluated the performance during cycling (S1,S2). The mean work produced by the affected leg (Figure 2(f)) at the end of the intervention was significantly superior in the experimental group with respect to the control group (MD [95% CI] = 8.13 [1.03, 15.25]; P = 0.02; 46 patients) with a moderate quality of the evidence. The unbalance between the work produced by the two legs during pedaling (Figure 2(g)) showed instead a positive but not statistically significant trend (MD [95% CI] = 7.80 [-3.69, 19.29]; P = 0.18; 46 patients) in favor of the experimental group with a low quality of the evidence.

I able I. Main cr	nara	ICTERISTICS OF THE IN	cinc	jed studies.						
Study	De	ssign, country and tting	Pai	rticipants	Intervention and	dosage	Con	trol and dosage	Relev	ant outcome measures
SI - Ambrosini et al. and Ambrosini ²⁵⁻²⁷	• • •	RCT Italy Rehabilitation unit (inpatient)	• • • • •	35 enrolled (17 Exp / 18 Con), 30 analyzed (15 Exp / 15 Con) 19 ischemic / 8 hemorrhagic / 3 TBI Age: 57.5 (12.2)* years TSI: 48.0 (39.7)* days	 Passive FES (25 minutes 5 weeks × 4 weeks × 4 weeks × 10 weeks Cadence = 1 	cycling + usual care + 180 minutes) × 5/ veeks ulation: Q, H, GM, TA requency: 20 Hz, PW: ent: above motor 20 rpm	• •	Passive cycling with placebo FES + usual care (25 minutes + 180 minutes) × 5/ weeks × 4 weeks	* • • • • • • • • •	0. Meter Walk Test Aotricity Index Frunk Control Test Jpright Control Test Work of the paretic leg edaling unbalance edaling unbalance iPMG of rectus femoris ind biceps femoris
S2 – Ambrosini et al. and Peri et al. ^{28,9}	• • •	RCT Italy Rehabilitation unit (inpatient)	• • • • •	68 enrolled (34 Exp / 34 Con) 68 analyzed (34 Exp / 34 Con) 55 ischemic / 9 hemorrhagic / 4 hematoma Age: 74.3 (12.2)* years TSI: 16.0 (10.8)* days	 Active FES-c (25 minutes (25 minutes) weeks × 3w weeks × 3w Wilateral Stimulation f Stimulation f 400 µs. curror threshold Cadence = 3 	ycling + UC + 50minutes) × 5/ eeks nulation: Q, H, TA, GL frequency: 20 Hz; PW: ent: above motor 20 rpm	• •	Usual care 75 minutes × 5/ weeks × 3 weeks	•••••••	äat Speed 5 Minute Walk Test Aeasure Aeasure Trunk Conrrol Test all Efficacy Scale Sait Spatial and temporal Aarameters Aarameters Aedaling unbalance Pedaling unbalance
S3 - Bauer et al. ³⁰	• • •	RCT Austria: Rehabilitation unit (inpatient)	• • • • •	40 enrolled (21 Exp / 19 Con), 37 analyzed (19 Exp /18 Con) 25 ischemic / 12 hemorrhagic Age: 61.4 (12.6)* years TSI: 52.3 (44.0)* day	 Active FES-c (20 minutes 4 weeks Unilateral sti Stimulation f PVV: 250 µs; comfortably 	ycling + usual care + N.A.) × 3/weeks × imulation: Q, H requency: 25 Hz; current: maximal porem	• •	Active cycling + usual care (20 minutes + N.A.) × 3/weeks × 4 weeks	• • • • •	unctional Ambulation Lategory erformance-Oriented Aobility Assessment balance sub-scale) Aotricity index Aodifies Ashworth Scale
54 - De Sousa et al. ³¹	•••	RCT Australia 2 Rehabilitation unit (inpatient)	••• ••	40 enrolled (20 Exp / 20 Con), 39 analyzed (19 Exp / 20 Con) 22 ischemic / 9 hemorrhagic / 7 TBI / 2 others Age: 61.0 (15.5)* years TSI: 36.0 (28.8)* days	 Active FES-c Active FES-c (17-32 minure (17-32 min	ycling + usual care tes + N.A.) × 5/weeks imulation: Q, H, TA, GL requency: 50 Hz; current: maximal tolerated 30 rpm	•	Usual care >60 minutes + 5/ weeks × 4 weeks	••••	Aobility trength of the knee xtensors trength of the key nuscles

(Continued)

Table I. (Conti	nued)						
Study	Design, country and setting	Pa	rticipants	Intervention and dosage	Control an	d dosage	Relevant outcome measures
SS - Ferrante et al. ³²	 RCT Italy Rehabilitation unit (inpatient) 	••••	20 enrolled (10 Exp / 10 Con), 20 analyzed (10 Exp / 10 Con) 15 ischemic / 5 hemorrhagic Age: 53.5 (10.7)* years TSI: 53.3 (23.7)* days	 Passive FES-cycling + usual care (35 minutes + 145 minutes) × 5/ weeks × 4 weeks Bilateral Stimulation: Q, H, GM, TA Stimulation frequency: NA; PW: NA; current: NA. Cadence = 40 rpm 	Usual of Usual of National Of Nationa	zare n × 5/weeks seks	 Trunk Control Test Morricity Index Upright Motor Control Test 50 Meter Walk Test Sit To Stand Trial Maximal Voluntary
S6 - Lee et al. ³³	 RCT Korea Rehabilitation unit (inpatient) 	• • • • •	l6 enrolled (8 Exp / 8 Con). l6 analyzed (8 Exp / 8 Con) l0 ischemic / 6 hemorrhagic Age: 63.3 (14.6)* years TSI: 59.9 (44.3)* days	 Active FES-cycling 30 minutes × 5/weeks × 4 weeks Unilateral Stimulation: Q, H, GM, TA Stimulation frequency: 60 Hz; PW: 300 µs; current: above motor threshold Cadence = 30 rmm 	 Active 30 minu weeks 	cycling utes \times 5/ \times 4 weeks	 Contra action Minute Walt Test Berg Balance Scale Korean-Modified Barthel Index Exercise Tolerance Test
S7 - Li et al. ³⁴	 RCT China Rehabilitation unit (inpatient) 	•••••	54 enrolled 52 analyzed (18 Exp / 17 Con Cl / 17 Con C2) 30 ischemic / 22 hemorrhagic Age: 60.5 (12.9)* years TSI: 14.9 (5.7)* days	 Active FES-cycling + usual care (30 minutes + 120 minutes) × 6/ weeks × 8 weeks Unilateral Stimulation: TA, GL Stimulation frequency: 25 Hz; PW: 250 µs; current: above motor threshold Cadence = N.A. 	 CI: Ac usual c: 40 usual c: 40 usual c: 40 usual c: 120min weeks C2: usu 120min weeks 	tive cycling + are uutes + nutes) × 6/ × 8 weeks Lal care nutes × 6/ × 8 weeks	 Composite Spasticity Scale Berg Balance Scale 10-m Walking Speed Modified Fugl-Meyer, lower limbs sub-scale
*Mean (standard devia FES: Functional Electri TA: Tibialis Anterior;	tion). cal Stimulation; GL: Gastrc TBI: Traumatic Brain Injury	ocnemi 7; TSI: ⁻	ius Lateralis; GM: Gluteus Maximum; H Time since injury. Exp: Experimental gr.	: Hamstrings; N.A.: Not Available; Q: Quadric oup; con: Control group.	eps; PW: pu	llse width; RCT:	Randomized controlled trial;

(a) 	Exp Mean	erimenta SD	ti Total	Co Mean	SD -	Total	S Weight	td. Mean Difference IV, Fixed, 95% CI	Std. Mean Difference IV, Fixed, 95% Cl
S1. Ambrosini et al 2011 and Ambrosini et al 2012	0.29	0.25	15	0.18	0.2	15	13.9%	0.47 [-0.25, 1.20]	
S2. Ambrosini et al 2020 and Peri et al 2016	0.19	0.19	34	0.17	0.19	34	32.5%	0.10 [-0.37, 0.58]	
S3. Bauer et al 2015 S5. Ferrante et al 2008	1.74	0.99	19	-0.02	0.33	18	15.8%	0.08 [-0.85, 1.01]	
S6. Lee et al 2013	72.62	84.34	8	40.5	59.04	8	7.4%	0.42 [-0.58, 1.41]	
S7. Li et al 2017	0.26	0.28	18	0.11	0.29	34	21.8%	0.52 [-0.07, 1.10]	
Total (95% CI) Haterogenerity: $Chi^2 = 4.52$, df = 5 (B = 0.48); $l^2 = 0$			102			119	100.0%	0.40 [0.13, 0.67]	→
Test for overall effect: $Z = 2.87$ (P = 0.004)									-2 -1 Ó İ Ż Favours [Control] Favours [Experimental]
b)	Experi	mental G	iroup	Con	trol Gro	oup		Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% C	IV, Fixed, 95% CI
S1. Ambrosini et al 2011 and Ambrosini et al 2012	69 70	29	15	55	29	15	15.2%	0.47 [-0.26, 1.20]	
S3. Bauer et al 2015	36	22	19	34	21	18	19.2%	0.09 [-0.55, 0.74]	
S4. De Sousa et al 2016	10.5	5.4	19	8.5	5	20	19.9%	0.38 [-0.26, 1.01]	
S5. Ferrante et al 2008	53	12	10	49	16	10	10.3%	0.27 [-0.61, 1.15]	
Total (95% CI)			97			97	100.0%	0.23 [-0.05, 0.51]	-
Heterogeneity: $Chi^2 = 1.08$, $df = 4$ (P = 0.90); $I^2 = 0\%$									-1 -0.5 0 0.5 1
Test for overall effect: $Z = 1.58 (P = 0.11)$									Favours [Control Favours [Experimental]
c)	Experi	mental C	iroup	Con	trol Gro	oup		Std. Mean Difference	Std. Mean Difference
Study of Subgroup	Mean	SD	Tota	Mean	SD 1	Total	Weight	IV, Random, 95% Cl	IV, Kandom, 95% Cl
54. De 5053 et al 2016 57. Li et al 2017	10	0.82	18	8.16	1.24	34	50.0%	1.63 [0.97, 2.28]	•
Total (95% CI)			37			54	100.0%	0.49 [-1.74, 2.71]	
Heterogeneity: Tau ² = 2.47; Chi ² = 23.36, df = 1 (P < Test for overall effect: Z = 0.43 (P = 0.67)	0.0000	1); I ² = 9	6%						-4 -2 0 2 4 Favours [Control] Favours [Experimental]
(b								6.1.1. B.W.	6.1.1. B.W.
Study or Subgroup	Experi Mean	mental C SD	Total	Mean	troi Gro SD	Total	Weight	IV, Random, 95% C	Std. Mean Difference IV, Random, 95% CI
S2. Ambrosini et al 2020 and Peri et al 2016	38	14	34	33	16	34	27.3%	0.33 [-0.15, 0.81]	+
S3. Bauer et al 2015	6	4.36	19	4	4.24	18	25.7%	0.45 [-0.20, 1.11]	+
S6. Lee et al 2013	47.13	6.98	8	51.63	2.5	8	21.6%	-0.81 [-1.84, 0.22]	
57. Li et al 2017	50.5	2.08	10	44.93	2.90	54	23.4%	1.91 [1.25, 2.60]	
Total (95% Cl) Heterogeneity: Tau ² = 0.76; Chi ² = 22.62, df = 3 (P < Test for overall effect: Z = 1.09 (P = 0.28)	0.0001)	; I ² = 87	79 %			94	100.0%	0.52 [-0.41, 1.45]	-4 -2 0 2 Favours [Control] Favours [Experimental]
e)	Experin	nental G	roup	Con	trol Gro	up		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
S1. Ambrosini et al 2011 and Ambrosini et al 2012 S2. Ambrosini et al 2020 and Pari et al 2016	78	25	15	67	17	15	20.4%	11.00 [-4.30, 26.30]	
S2. Ambrosini et al 2020 and Peri et al 2016 S5. Ferrante et al 2008	93 75.9	21.71	34 10	84 75.4	15.37	34 10	62.1% 17.5%	9.00 [0.23, 17.77] 0.50 [-15.99, 16.99]	
Total (95% CI)			59			59	100.0%	7.92 [1.01, 14.82]	
Heterogeneity: $Chi^2 = 0.99$, $df = 2$ (P = 0.61); $I^2 = 0\%$									-20 -10 0 10 20
Test for overall effect: Z = 2.25 (P = 0.02)									Favours [Control] Favours [Experimental]
f)	Experir	nental G	roup	Cont	trol Gro	up		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
S2. Ambrosini et al 2011 and Ambrosini et al 2012 S2. Ambrosini et al 2020 and Peri et al 2016	13.28	13.25	15	5.79 18.43	5.87 11.03	15	77.5% 22.5%	7.49 [-0.58, 15.56] 10.34 [-4.65, 25.33]	
Total (95% CI)			23			23	100.0%	8.13 [1.03, 15.24]	
Total (95% CI) Heterogeneity: Chi ² = 0.11, df = 1 (P = 0.74); i ² = 0% Test for overall effect: Z = 2.24 (P = 0.02)			23			23	100.0%	8.13 [1.03, 15.24]	-20 -10 0 10 20
Total (95% Cl) Heterogeneity: Chi ² = 0.11, df = 1 (P = 0.74); l ² = 0% Test for overall effect: Z = 2.24 (P = 0.02)			23			23	100.0%	8.13 [1.03, 15.24]	-20 -10 0 10 20 Favours [Control] Favours [Experimental]
Total (95% CI) Heterogeneity: Chi ² = 0.11, df = 1 (P = 0.74); t ² = 0% Test for overall effect: Z = 2.24 (P = 0.02) Study or Subarnun	Experin	nental Gr	23	Cont	rol Gro	23 up Total	100.0%	8.13 [1.03, 15.24] Mean Difference	-20 -10 0 10 20 Favours [Control] Favours [Experimental] Mean Difference
Total (95% CI) Heterogeneity: Chi ² = 0.11, df = 1 (P = 0.74); l ² = 0% Test for overall effect: Z = 2.24 (P = 0.02) <u>(P)</u> Study or Subgroup S1. Ambrosini et al 2011 and Ambrosini et al 2012	Experin Mean 47	nental Gr SD 35	23 roup Total 15	Cont Mean 25	rol Gro SD 32	23 up Total 15	100.0% Weight 22.9%	8.13 [1.03, 15.24] Mean Difference IV, Fixed, 95% CI 22.00 [-2.00, 46.00]	-20 -10 0 10 20 Favours [Control] Favours [Experimental] Mean Difference IV, Fixed, 95% CI
Total (95% CI) Heterogeneity: Chi ² = 0.11, df = 1 (P = 0.74); l ² = 0% Test for overall effect: Z = 2.24 (P = 0.02) D Study or Subgroup S1. Ambrosini et al 2011 and Ambrosini et al 2012 S2. Ambrosini et al 2020 and Peri et al 2016	Experin Mean 47 80.34	nental Gr SD 35 13.78	23 roup Total 15 8	Cont <u>Mean</u> 25 76.76	rol Gro SD 32 12.92	23 up Total 15 8	100.0% Weight 22.9% 77.1%	8.13 [1.03, 15.24] Mean Difference IV, Fixed, 95% CI 22.00 [-2.00, 46.00] 3.58 [-9.51, 16.67]	-20 -10 0 10 20 Favours [Control] Favours [Experimental] Mean Difference IV, Fixed, 95% CI
Total (95% CI) Heterogeneity: Ch ² = 0.11, df = 1 (P = 0.74); l ² = 0% Test for overall effect: Z = 2.24 (P = 0.02) <u>Study or Subgroup</u> Study or <u>Subgroup</u> S1. Ambrosini et al 2011 and Ambrosini et al 2012 S2. Ambrosini et al 2020 and Peri et al 2016 Total (95% CI)	Experin Mean 47 80.34	nental Gr SD 35 13.78	23 roup Total 15 8 23	Cont Mean 25 76.76	rol Gro SD 32 12.92	23 up <u>Total</u> 15 8 23	100.0% Weight 22.9% 77.1% 100.0%	8.13 [1.03, 15.24] Mean Difference IV, Fixed, 95% C1 22.00 [-2.00, 46.00] 3.58 [-9.11.16.67] 7.80 [-3.69, 19.29]	-20 -10 0 10 20 Favours [Control] Favours [Experimental] Mean Difference IV, Fixed, 95% CI
Total (95% CI) Heterogeneiiy: Chi ² = 0.11, df = 1 (P = 0.74); l ² = 0% Test for overall effect: Z = 2.24 (P = 0.02) <u>3</u>) <u>51.4mbrosini et al 2011 and Ambrosini et al 2012</u> 52. Ambrosini et al 2011 and Ambrosini et al 2012 52. Ambrosini et al 2020 and Peri et al 2016 Total (95% CI) Heterogeneiiy: Chi ² = 1.74, df = 1 (P = 0.19); l ² = 43% Test for overall effect: Z = 1.33 (P = 0.18)	Experin Mean 47 80.34	nental Gr SD 35 13.78	23 roup Total 15 8 23	Cont Mean 25 76.76	rol Gro SD 32 12.92	23 up <u>Total</u> 15 8 23	100.0% Weight 22.9% 77.1% 100.0%	8.13 [1.03, 15.24] Mean Difference IV, Fixed, 95% CI 22.00 [-2.00, 46.00] 3.58 [-9.51, 16.67] 7.80 [-3.69, 19.29]	-20 -10 0 10 20 Favours [Control] Favours [Experimental] Mean Difference IV. Fixed, 95% Cl
Total (95% CI) Heterogeneity: Ch ² = 0.11, df = 1 (P = 0.74); l ² = 0% Test for overall effect: Z = 2.24 (P = 0.02) 2) Study or Subgroup 52. Ambrosini et al 2011 and Ambrosini et al 2012 52. Ambrosini et al 2020 and Peri et al 2016 Total (95% CI) Heterogeneity: Ch ² = 1.74, df = 1 (P = 0.19); l ² = 43% Test for overall effect: Z = 1.33 (P = 0.18)	Experin Mean 47 80.34	nental Gr SD 35 13.78	23 roup Total 15 8 23	Cont <u>Mean</u> 25 76.76	rol Gro SD 32 12.92	23 up <u>Total</u> 15 8 23	Weight 22.9% 77.1% 100.0%	8.13 [1.03, 15.24] Mean Difference IV. Fixed, 95% CI 22.00 [-2.00, 66.00] 3.58 [-9.51, 16.67] 7.80 [-3.69, 19.29]	-20 -10 0 10 20 Favours [Control] Favours [Experimental] Mean Difference IV, Fixed, 95% CI
Total (95% CI) Heterogeneiiy: Chi ² = 0.11, df = 1 (P = 0.74); l ² = 0% Test for overall effect: Z = 2.24 (P = 0.02) Study or Subgroup S1. Ambrosini et al 2011 and Ambrosini et al 2012 S2. Ambrosini et al 2020 and Peri et al 2016 Total (95% CI) Heterogeneiiy: Chi ² = 1.74, df = 1 (P = 0.19); l ² = 43% Test for overall effect: Z = 1.33 (P = 0.18) D)	Experin Mean 47 80.34 Experim	nental Gr SD 35 13.78	23 roup Total 15 8 23	Cont Mean 25 76.76	rol Gro SD 32 12.92	23 Total 15 8 23	100.0% Weight 22.9% 77.1% 100.0%	 8.13 [1.03, 15.24] Mean Difference IV, Fixed, 59% CI 22.00 [-2.00, 46.00] 3.58 [-9.51, 16.67] 7.80 [-3.69, 19.29] id. Mean Difference. by End Off C 	-20 -10 0 10 20 Favours [Control] Favours [Experimental] Mean Difference IV, Fixed, 95% Cl -50 -25 Favours [Control] Favours [Experimental] Stid, Mean Difference
Total (95% CI) Heterogeneity: Chi ² = 0.11, df = 1 (P = 0.74); l ² = 0% Test for overall effect: Z = 2.24 (P = 0.02) S1.Ambrosini et al 2011 and Ambrosini et al 2012 S1.Ambrosini et al 2020 and Peri et al 2016 Total (95% CI) Heterogeneity: Chi ² = 1.74, df = 1 (P = 0.19); l ² = 43% Test for overall effect: Z = 1.33 (P = 0.18) 1) Study or Subgroup S2. Ambrosini et al 2020 and Peri et al 2016	Experin 47 80.34 Experin Mean 66	nental Gr SD 35 13.78 Hental Gr SD 16	23 Total 15 8 23 Total Total 34	Contt Mean 25 76.76 Contti Mean 66	rol Gro SD 32 12.92	up Total 15 8 23 23	100.0% Weight 22.9% 77.1% 100.0% S Weight 82.1%	8.13 [1.03, 15.24] Mean Difference IV, Fixed, 95% CI 22.00 [-2.00, 46.00] 3.58 [-9.51, 16.67] 7.80 [-3.69, 19.29] td. Mean Difference IV, Fixed, 95% CI 0.00 [-0.48, 0.48]	-20 -20 Favours [Control] Favours [Experimental] Mean Difference IV, Fixed, 95% CI -50 -25 Favours [Control] Favours [Experimental] Std. Mean Difference IV, Fixed, 95% CI
Total (95% CI) Heterogeneity: Chi ² = 0.11, df = 1 (P = 0.74); l ² = 0% Test for overall effect: Z = 2.24 (P = 0.02) Study or Subgroup 51. Ambrosini et al 2011 and Ambrosini et al 2012 52. Ambrosini et al 2020 and Peri et al 2016 Total (P5% CI) Heterogeneity: Chi ² = 1.74, df = 1 (P = 0.19); l ² = 43% Test for overall effect: Z = 1.33 (P = 0.18) Sudy or Subgroup Sc. Ambrosini et al 2020 and Peri et al 2016 Sc. Ambrosini et al 2020 and Peri et al 2016 Sc. Lee et al 2013	Experim Mean 47 80.34 Experim Mean 66 84	nental Gr 35 13.78 nental Gr SD 16 8.59	23 Total 15 8 23 Total 34 8	Cont Mean 25 76.76 Cont Mean 66 90.25	rol Gro 32 12.92	23 up <u>Total</u> 15 8 23 up <u>Total</u> 34 8	100.0% Weight 22.9% 77.1% 100.0% S Weight 82.1% 17.9%	8.13 [1.03, 15.24] Mean Difference IV, Fixed, 95% CI 22.00 [-2.00, 46.00] 3.58 [-9.51, 16.67] 7.80 [-3.69, 19.29] xd. Mean Difference IV, Fixed, 95% CI 0.00 [-0.48, 0.48] -0.70 [-1.71, 0.32]	-20 -20 Favours [Control] Favours [Experimental] Mean Difference IV, Fixed, 95% CI -50 -25 Favours [Control] Favours [Experimental] Std. Mean Difference IV, Fixed, 95% CI
Total (95% CI) Heterogeneity: Chi ² = 0.11, df = 1 (P = 0.74); l ² = 0% Test for overall effect: Z = 2.24 (P = 0.02) Study or Subgroup S1. Ambrosini et al 2011 and Ambrosini et al 2012 S2. Ambrosini et al 2020 and Peri et al 2016 Total (95% CI) Heterogeneity: Chi ² = 1.74, df = 1 (P = 0.19); l ² = 43% Test for overall effect: Z = 1.33 (P = 0.18) S2. Ambrosini et al 2020 and Peri et al 2016 Total (95% CI) Test for overall effect: Z = 1.33 (P = 0.18)	Experin 47 80.34 Experin Mean 66 84	nental Gr SD 35 13.78 nental Gr SD 16 8.59	23 roup Total 15 8 23 roup Total 34 8 42	Cont Mean 25 76.76 Contr Mean 66 90.25	rol Gro SD 32 12.92	23 up <u>Total</u> 15 8 23 23 44 8 42	100.0% Weight 22.9% 77.1% 100.0% S Weight 82.1% 17.9% 100.0%	8.13 [1.03, 15.24] Mean Difference IV, Fixed, 95% CI 22.00 [-2.00, 46.00] 3.58 [-9.51, 16.67] 7.80 [-3.69, 19.29] V. Fixed, 95% CI 0.00 [-0.48, 0.48] -0.70 [-1.71, 0.32] -0.12 [-0.56, 0.31]	-20 -10 0 10 20 Favours [Control] Favours [Experimental] Mean Difference IV, Fixed, 95% Cl -50 -25 0 25 Favours [Control] Favours [Experimental] Std. Mean Difference IV, Fixed, 95% Cl
Total (95% CI) Heterogeneity: Chi ² = 0.11, df = 1 (P = 0.74); l ² = 0% Test for overall effect: Z = 2.24 (P = 0.02) S1 S1. Ambrosini et al 2011 and Ambrosini et al 2012 S2. Ambrosini et al 2020 and Peri et al 2016 Total (95% CI) Heterogeneity: Chi ² = 1.74, df = 1 (P = 0.19); l ² = 43% Test for overall effect: Z = 1.33 (P = 0.18) S2. Ambrosini et al 2020 and Peri et al 2016 S2. Ambrosini et al 2020 and Peri et al 2016 S2. Ambrosini et al 2020 and Peri et al 2016 S6. Lee et al 2013 Total (95% CI) Heterogeneity: Chi ² = 1.47, df = 1 (P = 0.23); l ² = 32%	Experin 47 80.34 5 Experin 66 84	nental Gr SD 35 13.78 nental Gr SD 16 8.59	23 roup Total 15 8 23 roup Total 34 8 42	Contt Mean 25 76.76 Mean 66 90.25	rol Groo 32 12.92	23 up <u>Total</u> 15 8 23 23 42	100.0% Weight 22.9% 77.1% 100.0% S Weight 82.1% 17.9% 100.0%	8.13 [1.03, 15.24] Mean Difference IV, Fixed, 95% CI 22.00 [-2.00, 46.00] 3.58 [-9.51, 16.67] 7.80 [-3.69, 19.29] td. Mean Difference IV, Fixed, 95% CI 0.00 [-0.48, 0.48] -0.70 [-1.71, 0.32] -0.12 [-0.56, 0.31]	-20 -10 0 10 20 Favours [Control] Favours [Experimental] Mean Difference IV. Fixed, 95% Cl -50 -25 Favours [Control] Favours [Experimental] Std. Mean Difference IV. Fixed, 95% Cl

Figure 2. Forest plots of comparison at the short-term follow-up: Experimental (FES-cycling training (plus usual care)) versus Control Group (cycling alone and/or usual care). The training effects were computed starting from change from baseline for outcome a (Walking short distances) and post-intervention data for outcomes from b to h. (a) Walking short distances, (b) Muscle power functions of the lower limbs, (c) Tone of muscles of lower half of body[§], (d) Maintaining a standing position, (e) Maintaining a sitting position, (f) Mobility other specified, mean work produced by the paretic leg, (g) Mobility other specified, pedaling unbalance[§], and (h) Basic activities of daily living. **[AQ: 1]** [§]For outcomes with a negative direction of improvement, values in the meta-analysis were reported as superior value of the range minus the actual value of the outcome.



Figure 3. Summary of findings for the main comparisons.

Finally, no significant difference, with a low quality of the evidence, was found between the two intervention groups in the capability to perform activities of daily living: (SMD [95% CI] = -0.12 [-0.56; 0.31], P = 0.57; 84 patients; two studies).

Figure 3 summarizes the main findings of this systematic review on the effect at short-term follow-up. When the results of the meta-analysis for the primary outcome was transformed in gait speed, a significant between-group difference of 0.08 m/s [0.02; 0.13] was found in favor of patients performing cycling induced by functional electrical stimulation. No significant difference was found for

muscle power, capability to maintain a standing position and activities of daily life. The quality of the evidence ranged from low to moderate: it was only downgraded due to serious imprecision (total number of participants <300) and in two cases also for unexplained heterogeneity ($I^2 > 25\%$).

Treatment Effects at intermediate-term follow-up

Two studies (S1,S2) assessed the treatment effects on walking short distances, muscle power functions and capability to maintain a sitting position at



Figure 4. Forest plots of comparison at the intermediate-term follow-up: Experimental (FES-cycling training (plus usual care)) versus Control Group (cycling alone and/or usual care). The training effects were computed starting from intermediate-term follow-up data. (a) Walking short distances, (b) Muscle power functions of the lower limbs, and (c) Maintaining a sitting position.[AQ: 2]

intermediate-term follow-up on a total of 98 patients. No baseline imbalance was found, and meta-analyses were performed on intermediate-term follow-up values (Figure 4). Regarding walking short distances (Figure 4(a)), a near-threshold significant difference with a moderate quality of the evidence was found between the two intervention groups (MD [95% CI] = 0.14 [0.00, 0.28], P = 0.06). No significant differences (Figure 4(b-c)) were found, with a low quality of the evidence, for muscle power (MD [95% CI] = 5.97 [-9.20, 21.13], P = 0.44) and capacity of maintaining a sitting position (MD [95% CI] = 6.79 [-8.71, 22.29]; P = 0.39).

Adverse events and patients' satisfaction

In the only study (S2) which reported information about adverse events, no adverse events were highlighted for neither intervention groups. No studies evaluated the patients' satisfaction with the intervention.

Discussion

This systematic review, gathering information from seven randomized controlled trials recruiting a total of 273 subacute stroke patients, showed that cycling training augmented by functional electrical stimulation induces a significant improvement on walking ability, work produced by the paretic leg during pedaling and capability to maintain a sitting position with respect to other treatments not involving the use of functional electrical stimulation at short term follow-up. For what concerns other secondary outcome measures, for example, muscle power functions and tone of the lower limbs, capability to maintain a standing position, and to perform activities of daily living, no difference was found. Finally, no significant differences were found at intermediate-term follow-up in terms of walking, muscle power and capability to maintain a sitting position. Overall, the quality of the evidence ranged from low to moderate.

Due to the crucial role of locomotion recovery for independence and home return after stroke,³⁶ the capability of walking short distances was chosen as the primary outcome of this systematic review. Six out of 7 included studies evaluated this outcome and could be pooled in a meta-analysis, which showed a statistically significant difference between the two interventions (SMD [95% CI] = 0.40 [0.13, 0.67]; Figure 2(a)). When transformed in gait speed, a difference of 0.08 m/s was found in favor of the experimental group (Figure 3), below the minimal clinically important difference estimated in subacute stroke survivors for gait speed (e.g. 0.16 m/s^{36}). Therefore, despite statistically significant improvements, cycling training induced by functional electrical stimulation is not clinically superior to usual care based on gait-related outcome measures. A similar result was achieved by a recent systematic review,10 which evaluated the effects of cycling training (with no electrical stimulation) on the 10-m walking speed in stroke survivors (SMD [95% CI] = 0.30 [0.05, 0.50]). It is important to mention that in our meta-analysis, 4 out of 6 included studies explicitly performed cycling training without electrical stimulation in the control group, and therefore our results might show the additional benefits, on the top of cycling training alone, of using functional electrical stimulation synchronized to the cycling movement. These additional benefits might be explained by the enhanced afferent feedback evoked by electrical stimulation, which favors neural plasticity.³⁷

Previous systematic reviews with meta-analyses evaluated the general effects of functional electrical stimulation (not necessarily combined with cycling training) on walking compared to usual care or no intervention.^{1,5,38} Two of these reviews^{5,38} were focused on chronic stroke survivors and showed small to moderate effects on gait speed and walking distance. The third review¹ included studies whose participants were affected by a stroke with any chronicity and showed a small significant effect of gait speed (SMD [95% CI] = 0.08 [0.02, 0.15]). However, none of these reviews was focused neither on subacute stroke survivors nor on the specific effects of cycling training combined with functional electrical stimulation.

Regarding muscle power functions of the lower limb and capability to maintain a standing position, only positive trends in favor of the experimental group was found, but the meta-analyses did not find significant between-group differences. This suggests that the improvement of walking was not strictly correlated nor to higher muscle strength neither to an improved balance. However, the effect on balance (SMD [95% CI] = 0.52 [-0.41, 1.45]; P = 0.28; 173 patients; 4 studies) has to be considered with caution, since it was based on a low number of studies and was affected by a high heterogeneity. In a previous review,¹⁰ cycling with functional electrical stimulation revealed a significant effect on balance (SMD [95%] = 1.48[0.99, 1.97]) compared with cycling alone. Nevertheless, that result was based only on two^{30,33} out of the four currently available studies assessing the effects of cycling induced by functional electrical stimulation on balance.

Cycling training induced by functional electrical stimulation showed to improve the capability to maintain a sitting position and to increase the work produced by the paretic leg during pedaling, two aspects which are specific of the type of training performed.

Finally, the benefits for muscle tone and activities of daily living remained controversial, with only two studies, characterized by a high heterogeneity, evaluating these outcomes. Outcome measures evaluating the capability of performing daily self-care activities should be included in future randomized controlled trials, due to the crucial role of this domain for the quality of life of stroke survivors.

The improvements achieved at the end of the intervention were not maintained at intermediateterm follow-up. Indeed, only a positive trend, but not a significant difference, was found in favor of cycling with functional electrical stimulation for what concerns walking short distances and no differences were found for muscle power and capability to maintain a sitting position. However, these results have to be interpreted with caution since they were based on only two studies (S1, S2). Therefore, we advocate for future studies to foresee follow-up visits evaluating the effects of cycling with functional electrical stimulation at intermediate and long term.

In terms of methodological quality, four out of seven studies were judged as at low risk of bias. The main source of bias was related to the blinding procedure: in four out of seven studies the assessors were blind, but in almost all studies both participants and personnel were aware of group assignment. In only one study (S1), the control group was involved in a cycling training with placebo functional electrical stimulation in order to assure the blindness of participants. However, this limitation is widespread among rehabilitation studies in which the training requires the use of specific equipment. Other potential sources of bias derived from the lack of intention-to-treat analysis, which characterized three out of seven studies, and the poor evaluation of the compliance to the intervention, reported in only two studies (S2, S4).

Overall, the quality of the evidence ranged from low to moderate and therefore all the results should be interpreted carefully. Indeed, all meta-analyses included an overall sample size lower than 300, with a maximum of 221 patients for the primary outcome, and in many cases, there was a high heterogeneity between the studies.

Based on the available results, cycling training with functional electrical stimulation can be considered a safe and well-accepted intervention for stroke survivors; indeed, none of the included studies reported adverse events due to the training, and the drop-out rates were balanced between intervention groups.

A common limitation in all the included studies but one (S2) was the mean age of the participants, between 53 (S5) to 63 (S6) years old, below the mean age of stroke survivors (e.g. 73 years).³⁹ To increase the generalizability of the results, we strongly advocate clinical researchers to carry out randomized controlled trials with no limitation on the age of the participants.

This systematic review has some limitations. First, although unlikely, we could have lost some studies and we did not search through unpublished literature. Second, the included studies were characterized by a high heterogeneity: they differed from the type of cycling training delivered to the experimental group (e.g. passive versus active pedaling; electrical stimulation delivered to both legs or only to the affected leg; electrical stimulation provided to different muscle groups; different stimulation parameters; etc.), from the types of intervention delivered to the control group (only usual care versus usual care plus cycling training), from the outcome measures and from the number of training sessions. The low number of included studies did not allow to perform sub-group analyses, preventing us to derive any conclusions about the best training parameters. Third, the meta-analysis

evaluating the effect on walking short distances was based on change values since one study was characterized by a baseline imbalance. Fourth, the effects at intermediate-term follow-up have to be considered with caution since they were based only on two studies. Lastly, many of the included studies had small sample sizes, overall decreasing the quality of the evidence.

Based on our results, cycling training with functional electrical stimulation cannot be recommended in terms of being better than usual care. However, this type of intervention might be used as a labor-efficient alternative to usual care. Indeed, due to the low supervision required, cycling training with functional electrical stimulation can be safely performed in group sessions. Furthermore, it could be a valid option for home training. Highquality randomized controlled trials, recruiting larger sample sizes with no limitation on the participants' age, including long-term follow-up and assessing activities of daily living, are needed to drive final conclusions about the effectiveness of cycling training with functional electrical stimulation. Future research should also attempt to identify the optimal training regimen in order to maximize the therapeutic outcomes.

Clinical messages

- Patients with subacute stroke performing cycling training induced by functional electrical stimulation achieved a significant but not clinically relevant improvement in walking ability.
- Current evidence of the effect of cycling training induced by functional electrical stimulation relies on a limited number of studies.
- Further investigations are required to determine the optimal training parameters and to evaluate long-term effects.

Authors' Contribution

- EA was responsible for conceiving and designing the study, literature search, study selection, data extraction, risk of bias assessment, data synthesis and interpretation, drafting and critically revising the article, and approving the final version of the article.

- MP was responsible for literature search, study selection, data extraction, risk of bias assessment, analysis of treatment effects, data synthesis and interpretation, drafting and critically revising the article, and approving the final version of the article.
- GF was responsible for interpreting the data, critically revising the article, and approving the final version of the article.
- AP was responsible for conceiving and designing the study, critically revising the article, and approving the final version of the article.
- SF was responsible for conceiving and designing the study, critically revising the article, and approving the final version of the article.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding [GQ: 2]

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Research was partially supported by the Italian Ministry of Healthy (Grant number: GR-2010-2312228).

ORCID iDs [GQ: 3]

Emilia Ambrosini D https://orcid.org/0000-0002-6527 -0779

Giorgio Ferriero D https://orcid.org/0000-0002-7873 -6777

Supplemental material

Supplemental material for this article is available online.

References

- Howlett OA, Lannin NA, Ada L, et al. Functional electrical stimulation improves activity after stroke: a systematic review with meta-analysis. *Arch Phys Med Rehabil* 2015; 96(5): 934–943.
- Popović DB. Advances in functional electrical stimulation (FES). J Electromyogr Kinesiol 2014; 24(6): 795–802.
- Kafri M and Laufer Y. Therapeutic effects of functional electrical stimulation on gait in individuals post-stroke. *Ann Biomed Eng* 2015; 43(2): 451–466.

- Ferrante S, Bejarano NC, Ambrosini E, et al. A personalized multi-channel FES controller based on muscle synergies to support gait rehabilitation after stroke. *Front Neurosci* 2016; 10: 425.
- Robbins SM, Houghton PE, Woodbury MG, et al. The therapeutic effect of functional and transcutaneous electric stimulation on improving gait speed in stroke patients: a meta-analysis. *Arch Phys Med Rehabili* 2006; 87(6): 853–859.
- Barbosa D, Santos CP and Martins M. The application of cycling and cycling combined with feedback in the rehabilitation of stroke patients: a review. *J Stroke Cerebrovasc Dis* 2015; 24(2): 253–273.
- Ambrosini E, Parati M, Peri E, et al. Changes in leg cycling muscle synergies after training augmented by functional electrical stimulation in subacute stroke survivors: a pilot study. *J Neuroeng Rehabil* 2020; 17(1): 35.
- Raasch CC and Zajac FE. Locomotor strategy for pedaling: muscle groups and biomechanical functions. J Neurophysiol 1999; 82(2): 515–525.
- Mazzocchio R, Meunier S, Ferrante S, et al. Cycling, a tool for locomotor recovery after motor lesions? *NeuroRehabilitation* 2008; 23(1): 67–80.
- Shariat A, Ghayour M, Nakhostin N, et al. The effects of cycling with and without functional electrical stimulation on lower limb dysfunction in patients post-stroke : a systematic review with meta-analysis. *NeuroRehabilitation* 2019; 44(3): 389–412.
- Hunt KJ, Fang J, Saengsuwan J, et al. On the efficiency of FES cycling: a framework and systematic review. *Technol Health Care* 2012; 20(5): 395–422.
- Davis GM, Hamzaid NA and Fornusek C. Cardiorespiratory, metabolic, and biomechanical responses during functional electrical stimulation leg exercise: health and fitness benefits. *Artif Organs* 2008; 32(8): 625–629.
- Mayson TA and Harris SR. Functional electrical stimulation cycling in youth with spinal cord injury: a review of intervention studies. *J Spinal Cord Med* 2014; 37(3): 266–277.
- Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009; 6(7): e1000097.
- 15. World Health Organization. *International classification* of functioning, disability and health: *ICF*. World Health Organization, 2001.
- Furlan AD, Malmivaara A, Chou R, et al. 2015 updated method guideline for systematic reviews in the Cochrane Back and Neck Group. *Spine (Phila Pa 1976)* 2015; 40(21): 1660–1673.
- 17. Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011; 343, d5928.
- Higgins JPT and Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration, 2008. [AQ: 3]
- 19. Takeshima N, Sozu T, Tajika A, et al. Which is more generalizable, powerful and interpretable in meta-analyses,

mean difference or standardized mean difference? *BMC Med Res Methodol* 2014; 14, 30.

- Higgins JPT and Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002; 21(11): 1539–1558.
- Borenstein M, Hedges LV, Higgins JPT, et al. A basic introduction to fixed-effect and random-effects models for meta-analysis. *Res Synth Methods* 2010; 1(2): 97–111.
- 22. Nordic Cochrane Centre. *Review Manager (RevMan) version 5.3.* Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
- Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol* 2014; 14, 135.
- Guyatt G, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations *BMJ* 2008; 336(7650): 924–926.
- Ambrosini E, Ferrante S, Pedrocchi A, et al. Cycling induced by electrical stimulation improves motor recovery in postacute hemiparetic patients: a randomized controlled trial. *Stroke* 2011; 42, 1068–1073.
- Ambrosini E, Ferrante S, Molteni F, et al. FES-induced cycling improves locomotion in post-acute ischemic stroke patients: a randomized controlled trial. In: 16th Annual Conference of the International Functional Electrical Stimulation Society, 2011, pp. 1–3. [AQ: 4]
- Ambrosini E, Ferrante S, Ferrigno G, et al. Cycling induced by electrical stimulation improves muscle activation and symmetry during pedaling in hemiparetic patients. *IEEE Trans neural Syst Rehabil Eng* 2012; 20(3): 320–330.
- Ambrosini E, Peri E, Nava C, et al. A multimodal training with visual biofeedback in subacute stroke survivors: a randomized controlled trial. *Eur J Phys Rehabil Med* 2020; 56(1): 24–33.
- Peri E, Ambrosini E, Pedrocchi A, et al. Can FESaugmented active cycling training improve locomotion in post-acute elderly stroke patients? *Eur J Trans Myol* 2016; 26(3): 6063.
- 30. Bauer P, Krewer C, Golaszewski S, et al. Functional electrical stimulation-assisted active cycling - Therapeutic effects

in patients with hemiparesis from 7 days to 6 months after stroke: a randomized controlled pilot study. *Arch Phys Med Rehabil* 2015; 96(2): 188–196.

- de Sousa DG, Harvey LA, Dorsch S, et al. Functional electrical stimulation cycling does not improve mobility in people with acquired brain injury and its effects on strength are unclear: a randomised trial. *J Physiother* 2016; 62(4): 203–208.
- 32. Ferrante S, Pedrocchi A, Ferrigno G, et al. Cycling induced by functional electrical stimulation improves the muscular strength and the motor control of individuals with postacute stroke. Europa Medicophysica-SIMFER 2007 Award Winner. *Eur J Phys Rehabil Med* 2008; 44(2): 159–167.
- 33. Lee SY, Kang SY, Im SH, et al. The effects of assisted ergometer training with a functional electrical stimulation on exercise capacity and functional ability in subacute stroke patients. *Ann Rehabil Med* 2013; 37(5): 619–627.
- 34. Li Z, Fan J and Guo G. Effects of functional electrical stimulation combined with cycling active exercise of lower limbs in patients with early stroke. *Chinese J Rehabil Med* 2017; 32(6): 667–672.
- Perera S, Mody SH, Woodman RC, et al. Meaningful change and responsiveness in common physical performance measures in older adults. *J Am Geriatr Soc* 2006; 54(5): 743–749.
- Tilson JK, Sullivan KJ, Cen SY, et al. Meaningful gait speed improvement during the first 60 days poststroke: minimal clinically important difference. *Phys Ther* 2010; 90(2): 196–208.
- Kimberley TJ, Lewis SM, Auerbach EJ, et al. Electrical stimulation driving functional improvements and cortical changes in subjects with stroke. *Exp Brain Res* 2004; 154(4): 450–460.
- Pereira S, Mehta S, McIntyre A, et al. Functional electrical stimulation for improving gait in persons with chronic stroke. *Top Stroke Rehabil* 2012; 19(6): 491–498.
- European Registers of Stroke (EROS) Investigators, Heuschmann PU, Di Carlo A, et al. Incidence of stroke in Europe at the beginning of the 21st century. *Stroke* 2009; 40(5): 1557–1563.